Physician profile
Patrick E Heckman
NPI 1205332988
$3,829.46
in general payments reported to CMS, 2019-2025
51 companies · $2,633 in 2025
The $2,633 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $69.09 · 2024: $1,128 · 2025: $2,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715 · Education: $45.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,714.65 |
| Education | $45.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $378.12 | 2024-2025 | |
| Janssen Biotech, INC. | $313.92 | 2024-2025 | Tecvayli, Rybrevant, Talvey |
| Pfizer INC. | $281.14 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $256.26 | 2024-2025 | Lynparza, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $210.03 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Celgene Corporation | $156.85 | 2024-2025 | Reblozyl, Opdivo |
| Eisai INC. | $116.01 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.12 | 2024-2025 | Opdivo, Opdualag |
| Incyte Corporation | $101.43 | 2024-2025 | Jakafi, Monjuvi |
| Inari Medical, INC. | $98.32 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $93.76 | 2025 | Fruzaqla, Iclusig |
| Array Biopharma INC | $88.45 | 2024-2025 | Mektovi, Braftovi, Xalkori |
| Lilly USA, LLC | $87.33 | 2022-2025 | Jaypirca, Verzenio |
| Ipsen Biopharmaceuticals, INC | $84.14 | 2024-2025 | Onivyde, Somatuline Depot |
| Adaptive Biotechnologies Corporation | $84.10 | 2024-2025 | Clonoseq |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Heckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.